

Laura Parkkinen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4020267/publications.pdf>

Version: 2024-02-01

38
papers

5,572
citations

147801

31
h-index

315739

38
g-index

40
all docs

40
docs citations

40
times ranked

6979
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. <i>Brain</i> , 2022, 145, 584-595.	7.6	65
2	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	21.4	198
3	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. <i>Acta Neuropathologica</i> , 2021, 141, 159-172.	7.7	107
4	Neuropathological evidence of body-first vs. brain-first Lewy body disease. <i>Neurobiology of Disease</i> , 2021, 161, 105557.	4.4	72
5	<scp>Humanâ€specific</scp> Transcriptome of Ventral and Dorsal Midbrain Dopamine Neurons. <i>Annals of Neurology</i> , 2020, 87, 853-868.	5.3	22
6	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	4.4	29
7	Detection of alphaâ€synuclein conformational variants from gastroâ€intestinal biopsy tissue as a potential biomarker for Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 722-736.	3.2	39
8	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	10.2	195
9	LRP10 in Î±-synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032-1033.	10.2	11
10	<i>DNAJC12</i> and dopaâ€responsive nonprogressive parkinsonism. <i>Annals of Neurology</i> , 2017, 82, 640-646.	5.3	60
11	MAPT Genetic Variation and Neuronal Maturity Alter Isoform Expression Affecting Axonal Transport in iPSC-Derived Dopamine Neurons. <i>Stem Cell Reports</i> , 2017, 9, 587-599.	4.8	53
12	Î±â€synuclein genetic variability: A biomarker for dementia in Parkinson disease. <i>Annals of Neurology</i> , 2016, 79, 991-999.	5.3	85
13	DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study. <i>Lancet Neurology</i> , The, 2016, 15, 1248-1256.	10.2	69
14	<scp>G</scp>ut <scp>F</scp>eelings <scp>Ab</scp>out Î±â€synuclein in <scp>G</scp>astrointestinal <scp>B</scp>iopsies: <scp>B</scp>iomarker in the <scp>M</scp>aking?. <i>Movement Disorders</i> , 2016, 31, 193-202.	3.9	56
15	Alphaâ€synuclein <scp>RT</scp>â€Qu<scp>IC</scp> in the <scp>CSF</scp> of patients with alphaâ€synucleinopathies. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 812-818.	3.7	388
16	Generation and characterization of novel conformation-specific monoclonal antibodies for Î±-synuclein pathology. <i>Neurobiology of Disease</i> , 2015, 79, 81-99.	4.4	116
17	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	2.9	178
18	The Significance of Î±-Synuclein, Amyloid-Î² ² and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. <i>Neurodegenerative Diseases</i> , 2014, 13, 154-156.	1.4	83

#	ARTICLE	IF	CITATIONS
19	Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α -synuclein BAC transgenic mouse. <i>Neurobiology of Disease</i> , 2014, 62, 193-207.	4.4	46
20	Parkin Disease. <i>JAMA Neurology</i> , 2013, 70, 571.	9.0	119
21	Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4016-25.	7.1	259
22	Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. <i>Molecular Genetics and Metabolism</i> , 2011, 103, 410-412.	1.1	40
23	Disentangling the Relationship between Lewy Bodies and Nigral Neuronal Loss in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 277-286.	2.8	106
24	Cardiovascular diseases and hippocampal infarcts. <i>Hippocampus</i> , 2011, 21, 281-287.	1.9	18
25	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. <i>Brain</i> , 2011, 134, 1493-1505.	7.6	497
26	Testing an aetiological model of visual hallucinations in Parkinson's disease. <i>Brain</i> , 2011, 134, 3299-3309.	7.6	132
27	Cerebrospinal Fluid β -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. <i>Archives of Neurology</i> , 2009, 66, 382-9.	4.5	747
28	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. <i>Brain</i> , 2009, 132, 1783-1794.	7.6	612
29	Can olfactory bulb biopsy be justified for the diagnosis of Parkinson's disease? Comments on "Olfactory bulb α -synucleinopathy has high specificity and sensitivity for Lewy body disorders". <i>Acta Neuropathologica</i> , 2009, 117, 213-214.	7.7	23
30	Staging/typing of Lewy body related α -synuclein pathology: a study of the BrainNet Europe Consortium. <i>Acta Neuropathologica</i> , 2009, 117, 635-652.	7.7	249
31	Concomitant progressive supranuclear palsy and multiple system atrophy: More than a simple twist of fate?. <i>Neuroscience Letters</i> , 2009, 467, 208-211.	2.1	19
32	Applicability of current staging/categorization of α -synuclein pathology and their clinical relevance. <i>Acta Neuropathologica</i> , 2008, 115, 399-407.	7.7	294
33	Systematic Appraisal Using Immunohistochemistry of Brain Pathology in Aged and Demented Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 423-432.	1.5	23
34	Assessment of α -Synuclein Pathology: A Study of the BrainNet Europe Consortium. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 125-143.	1.7	73
35	Widespread and abundant α -synuclein pathology in a neurologically unimpaired subject. <i>Neuropathology</i> , 2005, 25, 304-314.	1.2	71
36	Regional Distribution of α -Synuclein Pathology in Unimpaired Aging and Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 363-367.	1.7	109

#	ARTICLE	IF	CITATIONS
37	Morphogenesis of Lewy Bodies: Dissimilar Incorporation of α -Synuclein, Ubiquitin, and p62. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2003, 62, 1241-1253.	1.7	240
38	α -Synuclein pathology is highly dependent on the case selection. <i>Neuro pathology and Applied Neurobiology</i> , 2001, 27, 314-325.	3.2	69